Navigation Links
Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
Date:3/19/2012

EAST HANOVER, N.J., March 19, 2012 /PRNewswire/ -- Novartis Pharmaceuticals Corporation today announced that once-daily Arcapta™ Neohaler™ (indacaterol inhalation powder) 75 mcg is now available in the US and in pharmacies nationwide.

Arcapta Neohaler is indicated for the long-term maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Arcapta Neohaler is not indicated to treat asthma. It is also not indicated to treat acute deteriorations of COPD and should not be used as a rescue medication for acute symptoms.

Arcapta Neohaler is the only once-daily, 24-hour long-acting beta2-agonist (LABA) approved in the US for maintenance treatment of airflow obstruction in patients with COPD. Arcapta Neohaler is an inhaled, steroid-free COPD treatment.

Arcapta Neohaler 75 mcg was studied in a total of 641 COPD patients in two key Phase III trials lasting 12 weeks. The primary endpoint results at week 12 showed that Arcapta Neohaler significantly improved lung function (FEV1) at 24 hours compared to placebo. As a secondary endpoint, lung function (FEV1) improvements were seen at five minutes after the first dose compared to placebo, and improvements observed at week 4 were consistently maintained over the course of 12 weeks in both trials.

"Arcapta Neohaler represents an important new treatment option for the 14 million Americans living with COPD," said Andre Wyss, President, Novartis Pharmaceuticals Corporation. "The launch of Arcapta Neohaler is a significant milestone as we continue to establish a strong respiratory presence in the US market."

COPD is a common, preventable and treatable disease characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways of the lungs to noxious particles or gases. More than 14 millio
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data in NEJM shows Novartis drug Signifor® is first therapy to provide rapid, durable benefit for Cushings disease patients in Phase III study
2. FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery
3. Unity Management Group Subsidiary Announces First Contracts of 2012 with Purdue Pharma L.P. and Novartis
4. Endo Announces Potential Short-Term Supply Constraints of Certain Analgesic Medications as a Result of Temporary Shut Down of Novartis Facility
5. Novartis Consumer Health Inc. Issues Voluntary Nationwide Recall of Certain Over-the-Counter Products Due to Potential Presence of Foreign Tablets or Chipped or Broken Tablets or Gelcaps
6. Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
7. New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth
8. Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
9. Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
10. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
11. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)...  The number of retail health clinics in ... thanks to drug store chains, according to Kalorama Information.  ... downturn, retail clinic growth had been at a standstill, ... number of retail clinics reached nearly 1,600 according to ... Overview and 2014 Consumer Survey Results .  ...
(Date:10/30/2014)... 30, 2014 China Biologic Products, Inc. (NASDAQ: ... integrated plasma-based biopharmaceutical company in China ... third quarter 2014 financial results on Wednesday, November 5, ... Company,s management will hold a conference call at 7:30 ... is 8:30 p.m., Beijing Time on November 6, 2014, ...
(Date:10/30/2014)... , October 30, 2014 ... GG hilft beim Aufbau von Kuhmilchverträglichkeit     ... für Lebensmittelallergien bei Säuglingen und Kleinkindern. Der ... bei der Ernährung der Babys bzw. deren ... sich jedoch, dass sich bei einer beträchtlichen ...
Breaking Medicine Technology:Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3China Biologic to Report Third Quarter 2014 Financial Results 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 3
... Inc. (Nasdaq: REGN ) today announced that ... the U.S. Food and Drug Administration (FDA) for VEGF ... age-related macular degeneration (wet AMD).  Under the Prescription Drug ... review time from submission to FDA action is ten ...
... 22, 2011 ResearchDx announced today the official ... CDO. Recent FDA initiatives, such ... Co-Development Concept Paper, have spurred biopharmaceutical companies, interest ... companion diagnostics. The traditional Contract Research Organization (CRO), ...
Cached Medicine Technology:Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration 2Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration 3Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration 4Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration 5Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration 6Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration 7ResearchDx Launches Contract Diagnostics Organization (CDO) 2
(Date:10/30/2014)... Florida (PRWEB) October 30, 2014 Timothy, ... visit to Pompano Beach firefighters, showing that you are ... , Timothy met firefighters Tracey and Carl at ... Galuppi’s Restaurant and the Pompano Beach Chamber of Commerce. ... the fire truck, letting Timothy wear his real fireman’s ...
(Date:10/30/2014)... October 30, 2014 High efficacy ... concepts in the medical-grade skin care domain: Cosmederm, ... of uniquely potent topical dermatological products, today announces ... http://www.RefinitySkinScience.com ) with patented COSMEDERM®-7 anti-irritant technology. ... concentrations (50% and 70%) and a low pH ...
(Date:10/30/2014)... Cary, N.C. (PRWEB) October 30, 2014 ... consumer-driven health care, is increasing efforts to help people ... out-of-pocket expenses continue to increase for prescription drugs in ... provides valuable savings and resources to bridge the relationship ... , One of the biggest challenges people face today ...
(Date:10/30/2014)... Tara Haelle HealthDay ... -- More than 100 genes have been identified that ... report. And researchers say they are on their ... may contribute to the disorder. Autism spectrum disorders ... and social difficulties and repetitive behaviors. An estimated one ...
(Date:10/30/2014)... October 30, 2014 Dr. Joseph Furlin MD, ... website for his practices; OB GYN in Melrose Park, ... This website contains important information about each of the ... as downloadable patient forms in English and Spanish. The ... service pages on the website provide Dr. Furlin’s patients with ...
Breaking Medicine News(10 mins):Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 3Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 4Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2
... Bavarian Nordic,reports the successful completion of a ... who received either one or two doses of,IMVAMUNE(R) ... are seen as the pivotal step on the ... in order to achieve a BLA for healthy,subjects., ...
... CHICAGO, Nov. 29 , What: Join Zoraida Sambolin, co-anchor of the ... and Easter Seals at the 2007 Easter Seals Metropolitan ... event that benefits local Chicago programs ... with autism, including the new Therapeutic School and Center ...
... to lamotrigine use, research shows , THURSDAY, Nov. 29 ... drug lamotrigine in pregnant women with epilepsy can help reduce ... Lamotrigine, an epilepsy drug, is taken by pregnant women with ... defects. However, the drug has also been linked to increased ...
... this to a human ,fountain of youth, however , , THURSDAY, ... able to temporarily return old skin cells to their youthful ... "This gene gets more and more active with age," said ... at Stanford University. "It doesn,t exist to make us ...
... report the discovery of biological markers of prostate cancer ... shedding light on the genetic basis for the prostate ... is being presented today at the American Association for ... Disparities in Racial/Ethnic Minorities and the Medically Underserved, being ...
... A study led by a University of Pennsylvania biologist in ... widely held belief that mice are the main animal reservoir ... published in the Proceedings of the Royal Society B, demonstrates ... the four species that account for major outbreaks. , According to ...
Cached Medicine News:Health News:Bavarian Nordic Reports Positive Data from First EUA Enabling Study with IMVAMUNE(R) Smallpox Vaccine Candidate 2Health News:Easter Seals Festival of Trees Holiday Gala Will Make a Difference for Children and Adults With Autism 2Health News:Tracking Drug Levels Helps Pregnant Women With Epilepsy 2Health News:Gene Tweak Reverses Aging in Mouse Skin Cells 2Health News:Biological markers of prostate cancer shed light on cancer burden faced by African-American men 2Health News:University of Pennsylvania study reveals inconspicuous hosts in the Lyme disease epidemic 2
... for sample processing consists of a clear ... applied, a chemical-resistant polypropylene lid, and a ... handling. The manifold is designed for consistent ... samples simultaneously. Loading, washing, and elution steps ...
Holder for QIAGEN 96-well plates, for use with QIAvac 96;...
Replacement gaskets for the Empore 96 Well Vacuum Manifold Assembly, insure a tight seal....
... with hydrophobic PTFE membranes,Millex filter units ... for the sterilizing filtration of gases, ... for sterilizing or clarifying organic solutions. ... units are available with different outlet ...
Medicine Products: